{"organizations": [], "uuid": "d59544370962a070e0f13fe31695b40f8aa5d45c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2015/02/03/102393523-458815204.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/19746125/device/rss/rss.xml", "section_title": "Top News and Analysis (pro)", "url": "https://www.cnbc.com/2018/04/05/merck-shares-rise-after-barclays-upgrades-shares-downgrades-competitor-pfizer.html", "country": "US", "domain_rank": 767, "title": "Merck shares rise after Barclays upgrades shares, downgrades competitor Pfizer", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-04-05T15:47:00.000+03:00", "replies_count": 0, "uuid": "d59544370962a070e0f13fe31695b40f8aa5d45c"}, "author": "", "url": "https://www.cnbc.com/2018/04/05/merck-shares-rise-after-barclays-upgrades-shares-downgrades-competitor-pfizer.html", "ord_in_thread": 0, "title": "Merck shares rise after Barclays upgrades shares, downgrades competitor Pfizer", "locations": [], "entities": {"persons": [{"name": "john tlumacki", "sentiment": "none"}, {"name": "meacham", "sentiment": "none"}, {"name": "geoff meacham", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "barclays", "sentiment": "negative"}, {"name": "pfizer barclays", "sentiment": "negative"}, {"name": "pfizer gold merck", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "boston globe", "sentiment": "none"}, {"name": "merck  barclays", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Barclays upgraded Merck to overweight from equal weight on better opportunities versus its competition, while downgrading Pfizer to equal weight from overweight given the less likely chance of a \"transformative\" acquisition.\nAnalyst Geoff Meacham and his team also raised their price target on Merck by $2 to $64, a more than 17 percent increase from Wednesday's close. \n\"In our view, there is perhaps 15 to 20 percent of first-line lung market share 'up for grabs' in the U.S.,\" Barclays analyst Geoff Meacham and his team said in a Thursday report. Meacham also noted a better outlook versus key competitors, namely Bristol-Myers Squibb . \nMerck shares rose 1 percent in premarket trading Thursday above $55 a share. The stock has fallen 3 percent so far this year.\n\nMeacham and his team lowered their price target on Pfizer by $3 to $38, still more than 5 percent above Wednesday's close. \n\"In our view, current levels largely capture the upside for key products such as Prevnar, Ibrance, Xeljanz and Xtandi,\" the report said. \"Our previous Overweight rating was based on the potential for a transformative acquisition, which could accelerate the growth profile and provide a clearer strategic direction, which we now view as less likely in the near term\" based on recent interaction with management, including the CFO. \nPfizer shares were mildly lower in premarket trading Thursday. The stock is down 0.25 percent for the year so far.\n\nIn the Thursday report, the Barclays analysts also downgraded Biogen to equal weight from overweight.", "external_links": [], "published": "2018-04-05T15:47:00.000+03:00", "crawled": "2018-04-05T16:16:11.000+03:00", "highlightTitle": ""}